Zevra Therapeutics (FRA:1GDA) Other Long-Term Liabilities : €26.55 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Other Long-Term Liabilities?

Zevra Therapeutics's other long-term liabilities for the quarter that ended in Mar. 2024 was €26.55 Mil.

Zevra Therapeutics's quarterly other long-term liabilities increased from Sep. 2023 (€5.07 Mil) to Dec. 2023 (€28.63 Mil) but then declined from Dec. 2023 (€28.63 Mil) to Mar. 2024 (€26.55 Mil).

Zevra Therapeutics's annual other long-term liabilities increased from Dec. 2021 (€0.31 Mil) to Dec. 2022 (€13.74 Mil) and increased from Dec. 2022 (€13.74 Mil) to Dec. 2023 (€28.63 Mil).

Zevra Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Zevra Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Other Long-Term Liabilities Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Zevra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Zevra Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Zevra Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (FRA:1GDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ZVRA:USA 1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines